# Neurovascular Transduction During Exercise in Chronic Kidney Disease

Study · id `cardio:ct-nct02947750` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02947750](<https://clinicaltrials.gov/study/NCT02947750>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02947750

Browse, organ or system: Blood vessels; Kidneys  
Browse, condition area: High blood pressure; Kidney connections  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 150 participants.

## Technical summary

Registry record NCT02947750. Randomized; single masking; primary purpose supportive care. Start 2016-10 (actual); primary completion 2027-04-30 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose supportive care
- Phase: Phase 2
- Enrolled: 150 participants (planned count; ClinicalTrials.gov record NCT02947750, source copy `cardio:ctgov-nct02947750-2026-05-18`, retrieved 2026-10-26)
- Started: 2016-10 (actual) (ClinicalTrials.gov record NCT02947750, source copy `cardio:ctgov-nct02947750-2026-05-18`, retrieved 2026-10-26)
- Primary completion: 2027-04-30 (anticipated) (ClinicalTrials.gov record NCT02947750, source copy `cardio:ctgov-nct02947750-2026-05-18`, retrieved 2026-10-26)
- Completion: 2027-04-30 (anticipated) (ClinicalTrials.gov record NCT02947750, source copy `cardio:ctgov-nct02947750-2026-05-18`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT02947750, source copy `cardio:ctgov-nct02947750-2026-05-18`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02947750-2026-05-18`, retrieved 2026-10-26)

## The registry's words

- Brief title: Neurovascular Transduction During Exercise in Chronic Kidney Disease
- Acronym: NeurovEx
- Condition: Renal Insufficiency, Chronic
- Intervention (Drug): 6R-BH4
- Intervention (Other): 6R-BH4 placebo
- Intervention (Dietary supplement): Folic acid
- Intervention (Other): Exercise training
- Intervention (Other): Stretching
- Intervention (Dietary supplement): Histidine and beta-alanine supplementation
- Intervention (Other): Histidine and beta-alanine placebo
- Lead sponsor: Emory University
- Lead sponsor class: OTHER
- Collaborator: National Heart, Lung, and Blood Institute (NHLBI)
- Collaborator class: NIH

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry lists this organization as the lead sponsor: Emory University (`cardio:org-emory-university`)
- Registry lists this organization as a collaborator: National Heart, Lung, and Blood Institute (`cardio:nhlbi`)

## Provenance

Content hash: b6ed6a056ba977c372a0617083011b99792102f8d1f8cedb38cded33fc913d80
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
